Molecular Breast Imaging: How It Works & What to Expect

Molecular breast imaging (MBI) is a functional imaging technique that uses a small amount of radioactive tracer, injected into a vein, to reveal how breast tissue is behaving metabolically rather than simply showing its structure. Unlike mammography, which takes an X-ray picture of breast anatomy, MBI highlights areas where cells are unusually active, making it particularly useful for finding cancers that hide in dense breast tissue. The technology has gained traction as a supplemental screening tool, and the experience of getting one shares some similarities with a mammogram but differs in important ways.

The Basic Mechanism

MBI works by exploiting a simple biological principle: cancer cells are more metabolically active than normal tissue and tend to pull in certain chemical compounds at a higher rate. The tracer used is technetium-99m sestamibi, a mildly radioactive compound that gets taken up by mitochondria, the energy-producing structures inside cells.¹ Because cancer cells have more mitochondria and higher metabolic demands, the tracer accumulates there in much greater concentrations. Research measuring uptake in tissue samples found that carcinomas showed roughly five to six times the tracer concentration of surrounding normal tissue, a dramatic difference that makes tumors light up clearly on the images.²

A dedicated gamma camera then detects the tiny gamma rays emitted by the tracer. Early versions of these cameras were general-purpose machines not designed specifically for breast imaging, but modern MBI systems use compact, breast-dedicated dual-head gamma cameras built with cadmium zinc telluride (CZT) semiconductor detectors. This solid-state technology roughly doubles both the energy and spatial resolution compared with older detector materials, and the pixelated design allows the active imaging area to extend right to the edge of the detector so that breast tissue can be placed directly on it, similar to how the breast sits on a mammography plate.³ The result is an image that shows where the tracer has collected, with any hot spots flagged for further evaluation.

What the Procedure Feels Like

If you are scheduled for an MBI exam, the process begins with an intravenous injection of the technetium-99m sestamibi tracer, usually administered through a small butterfly needle in your arm or hand. The tracer circulates through your body and reaches your breast tissue within a few minutes. You will then be asked to sit in a chair in front of the gamma camera, and your breast is positioned between two detector plates and lightly compressed, much like a mammogram. The compression is generally lighter than what most people experience during a standard mammogram, though some pressure is still needed to hold the breast in place and bring the tissue close to the detectors.

Each view takes around ten minutes of imaging time, and both breasts are typically imaged in two views each, so the total appointment runs roughly 40 to 45 minutes from the start of imaging. You will need to hold still during each acquisition. There are no dietary restrictions beforehand, and no recovery time afterward. The tracer is excreted naturally by the body, primarily through the kidneys, over the following hours. The radiation dose from MBI has been a point of ongoing refinement; modern low-dose protocols have significantly reduced the amount of tracer used compared with early studies, bringing the whole-body effective dose closer to levels considered acceptable for screening purposes.

Why Dense Breasts Are the Primary Use Case

Mammography works by looking at differences in how X-rays pass through breast tissue. Dense breast tissue appears white on a mammogram, and so do many cancers, which means tumors can hide in the white background like a snowball in a snowstorm. This is not a rare problem: roughly half of women undergoing screening mammography have dense or heterogeneously dense breasts. In this group, mammography’s ability to find cancer drops substantially.

MBI sidesteps the density issue entirely because it is not looking at anatomy. It is looking at metabolic activity, which has nothing to do with how dense the surrounding tissue is. A screening trial in women with dense breasts found a cancer detection rate of 3.2 per 1,000 women screened with mammography alone, compared with 12.0 per 1,000 when MBI was added to mammography.⁴ That roughly fourfold increase in detection demonstrates how many cancers mammography was missing in these women. A separate study of nearly 1,700 women with dense breasts found that MBI picked up 13 cancers that mammography missed entirely, 11 of which were invasive, yielding an incremental cancer detection rate of about 8 per 1,000 screened.⁵

Head-to-head comparisons of diagnostic accuracy in dense breasts underscore the gap. In one study, mammography alone had a sensitivity of just 24%, meaning it caught fewer than one in four cancers in these women. When MBI was combined with mammography, sensitivity jumped to 91%.⁶ The specificity did drop slightly with the addition of MBI, from about 89% to 83%, meaning somewhat more false alarms, but that tradeoff is generally considered worthwhile given how many real cancers were being missed.

How MBI Compares to Breast MRI

Breast MRI is the other major supplemental screening tool for women at elevated risk. It has very high sensitivity and does not depend on breast density, so a natural question is why anyone would choose MBI instead. The answer comes down to a mix of practical factors.

MRI is expensive, often costing several times what an MBI exam costs. It requires contrast dye injection (gadolinium), takes longer, and can be difficult or impossible for women with claustrophobia, certain metal implants, or kidney problems. MRI also tends to produce a higher false-positive rate, leading to more callbacks and biopsies for things that turn out to be benign. MBI offers a middle ground: it catches substantially more cancers than mammography alone in dense breasts, costs less than MRI, and is generally better tolerated because the imaging setup resembles a mammogram rather than requiring the patient to lie in a tube.

That said, breast MRI remains the preferred supplemental tool for the highest-risk women, such as those with known BRCA gene mutations or a history of chest radiation. MBI has shown strong results in supplemental screening for women with dense breasts and intermediate risk, and it fills a practical gap for patients who cannot undergo or do not have access to breast MRI.

Factors That Affect Image Quality

Not all MBI images look the same, and one variable that can affect how easy it is to spot an abnormality is what researchers call background parenchymal uptake, the amount of tracer picked up by normal breast tissue. When the background is very active, small tumors can be harder to distinguish from the surrounding tissue, somewhat analogous to the density problem in mammography, though generally less severe.

Hormone use is one of the biggest influences on background uptake. In postmenopausal women, those taking systemic estrogen or progesterone were significantly more likely to have moderate or marked background uptake.⁷ Interestingly, hormonal contraceptives did not have the same effect in premenopausal women, and the day of the menstrual cycle did not appear to matter in that same large study. However, a smaller focused study found that in about 29% of premenopausal participants, background uptake did increase during the luteal phase compared with the follicular phase.⁸ Because of this, some facilities recommend scheduling MBI during the first half of the menstrual cycle if possible, though it is not universally required.

The practical takeaway is that if you are on hormone replacement therapy and scheduled for MBI, your radiologist should be aware, because increased background activity can influence how they interpret the images.

Detecting Different Types of Breast Cancer

Not all breast cancers look or behave the same, and MBI picks up some types more readily than others. Invasive ductal carcinoma (IDC), the most common form, tends to show up as a bright, well-defined mass on MBI and was significantly more likely to appear with marked intensity compared with invasive lobular carcinoma (ILC). IDC appeared at marked intensity in about 63% of cases, versus 32% for ILC.⁹

ILC, which is the second most common type and tends to grow in a more diffuse pattern rather than forming a distinct lump, was more likely to be invisible on MBI. Roughly 31% of lobular cancers were occult on MBI, compared with about 8% of ductal cancers.⁹ This does not mean MBI is poor at finding lobular cancer overall; it still detected all disease foci in about 89% of breasts with ILC. But it does mean that a negative MBI result carries slightly less reassurance when lobular cancer is a specific concern, and clinicians may lean more on MRI in those situations.

When Something Looks Suspicious but Isn’t Cancer

Like any imaging test, MBI can produce false positives, areas that light up with increased tracer uptake but turn out to be benign on biopsy. Early studies identified several common culprits: fibroadenomas (common benign breast lumps), inflammatory fat necrosis (scarred tissue from a prior injury or surgery), and complex sclerosing lesions.¹⁰ These conditions can involve increased cellular activity or inflammation, which pulls in more tracer even though no cancer is present.

In the supplemental screening studies of dense-breast populations, recall rates for MBI ranged around 7% to 8%, meaning roughly one in 12 or 13 women screened were called back for additional workup. The biopsy rate in one study was about 3.7%.⁵ These rates are generally comparable to or slightly lower than what is seen with screening breast MRI, which is one of MBI’s practical advantages. Still, if you undergo MBI and receive a callback, the odds are that the finding will be benign. The experience of a callback, with its associated anxiety and potential need for biopsy, is one of the real costs of any supplemental screening, and it is worth being mentally prepared for that possibility.

MBI-Guided Biopsy

When MBI finds a suspicious area that is not visible on mammography or ultrasound, the question becomes how to biopsy it. You cannot use mammographic guidance to target something that only shows up on MBI. Researchers have developed MBI-guided biopsy systems that allow a tissue sample to be taken while the breast is positioned in the gamma camera, so the suspicious uptake area can be targeted directly.¹¹ This is analogous to how stereotactic biopsy targets lesions seen only on mammography, or MRI-guided biopsy targets MRI-only findings. The development of a reliable MBI-guided biopsy system is important because without it, a cancer found only on MBI might require surgical biopsy, which is more invasive and expensive.

Monitoring Treatment Response

Beyond screening and diagnosis, MBI has a role in tracking how well a breast cancer is responding to chemotherapy given before surgery, known as neoadjuvant therapy. Because MBI measures metabolic activity, changes in how brightly a tumor lights up over the course of treatment can indicate whether the cancer is shrinking. A pilot study found a moderate correlation between what MBI showed and the actual residual tumor size after treatment, with the average tracer uptake ratio dropping from about 3.0 before treatment to about 1.4 after.¹² The correlation was statistically significant, though the relative decrease in uptake was not reliably predictive of pathologic response in that small study. This application remains an active area of research; for now, MRI is more commonly used for treatment monitoring, but MBI offers an alternative for patients who cannot undergo MRI.

Cost and Accessibility

One of MBI’s selling points has always been that it is less expensive than breast MRI, but how the costs actually shake out is worth examining. Adding MBI to mammography increases the per-patient screening cost, as you would expect. One analysis calculated that the cost per patient screened rose from about $176 for mammography alone to roughly $571 when MBI was added.¹³ That is a meaningful increase. But when the analysis looked at cost per cancer actually detected, the combination was cheaper, at about $47,600 per cancer found compared with roughly $55,900 for mammography alone.¹³ In other words, mammography by itself spends more money per cancer it catches because it misses so many in dense breasts, making each detection relatively expensive. Adding MBI finds enough additional cancers to bring that ratio down.

Insurance coverage for MBI varies. Some states have dense-breast notification laws that require insurers to cover supplemental screening when mammography shows dense tissue, but the specifics differ by state and by insurer. If you are considering MBI, it is worth checking with your insurance provider beforehand. Out-of-pocket costs, when applicable, are typically several hundred dollars, considerably less than what an out-of-pocket breast MRI would run.

Who Is a Good Candidate

MBI fits most naturally into the screening picture for women who have dense breast tissue and an intermediate lifetime risk of breast cancer, a group that represents a large number of women but for whom breast MRI may not be recommended or practical. Women at very high risk, such as those with BRCA mutations, are generally better served by breast MRI, which has more evidence behind it in that specific population. But for the larger group of women with dense breasts who fall below the MRI-recommendation threshold, MBI offers a meaningful improvement over mammography alone.

MBI is also useful in specific diagnostic scenarios: evaluating a suspicious finding seen on one modality but not another, assessing the extent of a known cancer before surgery, and monitoring chemotherapy response. Women who cannot tolerate MRI for any reason, whether because of claustrophobia, renal insufficiency, or implanted devices, may find MBI a viable alternative for supplemental imaging.

The Radiation Question

Because MBI involves injecting a radioactive tracer, radiation exposure is a legitimate concern and the most frequently raised criticism of the technology. Early protocols used higher doses that delivered a whole-body effective dose substantially above what a standard mammogram produces. Researchers recognized this as a barrier to screening use and have worked to reduce the administered dose. Current low-dose protocols use roughly half the tracer amount of early studies while maintaining diagnostic image quality, though the effective dose is still higher than a single mammogram.

The key question for any individual woman considering MBI is whether the cancer-detection benefit justifies the additional radiation, especially if she plans to have the exam annually over many years. For women at genuinely elevated risk due to breast density, the consensus in the imaging community has increasingly favored the view that the detection benefit outweighs the small additional radiation risk, particularly with modern low-dose protocols. For women with fatty, non-dense breasts where mammography already works well, the calculus is different, and MBI would not typically be recommended for routine screening.

If you are weighing this decision, it can help to frame it in context. You receive background radiation from natural sources every day, and the incremental dose from a low-dose MBI exam is a fraction of what you would receive from many common medical imaging procedures like an abdominal CT scan. That does not make the radiation zero, but it puts it in perspective for a test that finds three to four times as many cancers as mammography alone in the population it is designed for.